Aprea Therapeutics Q2 net loss widens to $3.6 million; cash at $41.2 million
Aprea Therapeutics reported results for the quarter ended June 30, 2026, showing a net loss of $3.6 million, up from $3.2 million a year earlier, and no grant revenue compared with $118,111 in the second quarter of 2025. The company said its cash can fund projected operations into the first quarter of 2028 and that it is expanding enrollment in its APR-1051 Phase 1 trial, with the next clinical data update expected in the fourth quarter of 2026.
Key points
- Net loss was $3.6 million, or $(0.07) per basic share, on about 53.5 million weighted-average shares, versus $3.2 million, or $(0.53) per share, on about 6.1 million shares in Q2 2025.
- Operating loss was $4.0 million, compared with $3.4 million in the second quarter of 2025; grant revenue was zero versus $118,111 a year earlier.
- Cash and cash equivalents were $41.2 million as of June 30, 2026, up from $14.6 million on December 31, 2025, which the company said funds operations into the first quarter of 2028.
- The company plans to enroll at least 50 patients in uterine serous carcinoma or cyclin E-overexpressing platinum-resistant ovarian cancer, with dose escalation and backfill completion expected in Q2 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.